HOME >> BIOLOGY >> NEWS
Faster immune system testing set to improve poultry quality

The EUREKA E! 2692 MOLECULAR TESTS project has developed a simple, fast and easy-to-apply test to assess the robustness of the immune system in poultry. The test can be performed in two days on blood samples from poultry houses, using equipment already available in poultry diagnostic laboratories. Current immune system tests are imprecise, expensive and take weeks providing information too late to be useful. Combining this test with new immune-system boosting drugs would improve poultry welfare, and result in cheaper and better quality poultry products for European consumers.

Poultry is the fastest growing livestock industry worldwide, benefiting from production and price advantages as well as being viewed as healthy food. A particular attraction is the relatively short turn around five to eight weeks for broiler chickens. However production involves intensive housing and management to maximise output leading to an increase incidence of disease. And, because poultry is a global industry, similar disease problems are found all over the world, as highlighted by the emergence of bird flu.

Useful research and preventive tool
Reduced immunity is a serious problem for commercial poultry producers worldwide. The major cause is viral infection. All viruses can cause immunosuppression to varying degrees but Marek's disease, infectious bursal disease and chicken anaemia are particular concerns. A simple test to identify flocks that have been immunosuppressed by non-apparent infections was needed. The new test is both a useful research tool and a way to provide poultry companies with an early warning for flocks that will experience secondary infections because of immunosuppression.

The MOLECULAR TESTS project is the outcome of research initiated at the University of Georgia and continued at the Institut Ruder Boskovic in Zagreb. Project leader Dr William Ragland of Zagreb Biotek in Croatia had the basic idea twenty years ago but he had
'"/>

Contact: Shiels Catherine
catherine.shiels@es.eureka.be
322-777-0969
EUREKA
19-Apr-2006


Page: 1 2

Related biology news :

1. Faster-acting antidepressants closer to becoming a reality
2. Faster, low cost sequencing technologies needed to drive era of personalized medicine
3. Faster method to create antibodies for disease research
4. Bursts of waves drive immune system soldiers toward invaders
5. A friendly foe -- Bacteria residing in the gut boost immune response to tumors
6. A stepwise retreat: How immune cells catch pathogens
7. Link between immune system and mammary gland could shed new light on breast cancer
8. Researchers discover method for identifying how cancer evades the immune system
9. Invertebrate immune systems are anything but simple, conference finds
10. Mucosal-surface immune function discoveries could boost vaccine research
11. LIAI researchers identify a potential role for retinoic acid in autoimmune and inflammatory diseases

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Faster immune system testing set improve poultry quality

(Date:5/21/2013)... occur in the body, stem cells in the ... differentiating into mature immune cells that can fight ... deplete these cell populations, potentially leading to the ... Now, a team of researchers led by biologists ... found that, in mouse models, the molecule microRNA-146a ...
(Date:5/21/2013)... University researchers have developed a new method for ... holes in the cell surface. The technique could ... related biological fields. , Bulk electroporation a ... reversible nanopores in the cell membrane that are ... is an increasingly popular method of cell transfection. ...
(Date:5/21/2013)... new University of Michigan Water Center today awarded ... Great Lakes restoration and protection efforts. , The ... diverse projects, including efforts to track the remediation ... techniques to control non-native weedy plant invasions; study ... fish responses to restoration activities. , The grants ...
Breaking Biology News(10 mins):Keeping stem cells strong 2Single-cell transfection tool enables added control for biological studies 2U-M Water Center awards $570K in Great Lakes restoration grants 2U-M Water Center awards $570K in Great Lakes restoration grants 3U-M Water Center awards $570K in Great Lakes restoration grants 4
(Date:5/21/2013)... Wisc. (PRWEB) May 21, 2013 ... parts distributor , will be exhibiting for the ... Advancement of Medical Instrumentation (AAMI) 2013 Conference and ... purchase, support, distribute, and manufacture healthcare technologies. This ... in Long Beach, California. , The three-day ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... Canada (PRWEB) May 21, 2013 ... is a strong push within the industry to ... and Manufacturing Organizations and pharma companies often means ... frames. , Microtablets, developed in collaboration with Sensidose ... effective outsourcing can bring products to market sooner. ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: